Inhibition of Group IVA Cytosolic Phospholipase A2by Novel 2-Oxoamides in Vitro, in Cells, and in Vivo

Authors:

Abstract
The Group IVA cytosolic phospholipase A2 (GIVA PLA2) is a particularly attractive target for drug development because it is the rate-limiting provider of proinflammatory mediators. We previously reported the discovery of novel 2-oxoamides that inhibit GIVA PLA2 [Kokotos, G.; et al. J. Med. Chem. 2002, 45, 2891−2893]. In the present work, we have further explored this class of inhibitors and found that the 2-oxoamide functionality is more potent when it contains a long 2-oxoacyl residue and a free carboxy group. Long-chain 2-oxoamides based on γ-aminobutyric acid and γ-norleucine are potent inhibitors of GIVA PLA2. Such inhibitors act through a fast and reversible mode of inhibition in vitro, are able to block the production of arachidonic acid and prostaglandin E2 in cells, and demonstrate potent in vivo anti-inflammatory and analgesic activity.

This publication has 31 references indexed in Scilit: